Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks

por Guthrie, Heather, Honig, Lawrence S., Lin, Helen, Sink, Kaycee M., Blondeau, Kathleen, Quartino, Angelica, Dolton, Michael, Carrasco-Triguero, Montserrat, Lian, Qinshu, Bittner, Tobias, Clayton, David, Smith, Jillian, Ostrowitzki, Susanne
Publicado 2020

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

por Rios‐Romenets, Silvia, Lopera, Francisco, Sink, Kaycee M., Hu, Nan, Lian, Qinshu, Guthrie, Heather, Smith, Jillian, Cho, William, Mackey, Howard, Langbaum, Jessica B., Thomas, Ronald G., Giraldo‐Chica, Margarita, Tobon, Carlos, Acosta‐Baena, Natalia, Muñoz, Claudia, Ospina, Paula, Tirado, Victoria, Henao, Eliana, Bocanegra, Yamile, Chen, Kewei, Su, Yi, Goradia, Dhruman, Thiyyagura, Pradeep, VanGilder, Paul S., Luo, Ji, Ghisays, Valentina, Lee, Wendy, Malek‐Ahmadi, Michael H., Protas, Hillary D., Chen, Yinghua, Quiroz, Yakeel T., Reiman, Eric M., Tariot, Pierre N.
Publicado 2020